Welcome to our dedicated page for Optimi Health SEC filings (Ticker: OPTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Optimi Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Optimi Health's regulatory disclosures and financial reporting.
Optimi Health Corp. (OPTH) plans to launch a multisite Phase 2 clinical trial of psilocybin-assisted therapy for major depressive disorder (MDD) in the first half of 2027, with dosing expected to be completed by the end of 2027. The Health Canada–authorized study will enroll up to 200 participants across multiple Canadian sites and test the safety and efficacy of a single supervised dose of naturally derived psilocybin. The primary efficacy endpoint is change in Montgomery-Åsberg Depression Rating Scale (MADRS) score from baseline. Optimi will supply its own GMP-manufactured psilocybin, retain exclusive ownership of trial results, and states it can comfortably fund the trial with current cash on hand.
Optimi Health Corp. (OPTH), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, reported that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York, held September 14-16, 2026. A company presentation will be available on demand starting September 11, 2026, at 7:00 a.m. ET, and management plans to be available for one-on-one meetings throughout the conference. Optimi manufactures and distributes GMP-grade MDMA and botanical psilocybin drug products from its facilities in British Columbia, supplying active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally.
Optimi Health Corp. (OPTH) is registering up to 21,943,260 common shares for resale by Seven Knots, LLC under a common share purchase agreement and related convertible commitment notes. This consists of up to 21,276,593 Seven Knots Purchase Shares and up to 666,667 Seven Knots Commitment Shares issuable upon conversion of non‑interest‑bearing commitment notes.
The company will not receive proceeds from Seven Knots’ resale of these shares or from conversion of the commitment notes, but may receive up to $100 million in aggregate gross proceeds from selling common shares to Seven Knots over time. The registered shares equal about 383.2% of the current 5,725,867 outstanding shares, implying up to 27,669,127 shares if all are issued, which Optimi warns could significantly pressure its share price and future equity financing ability.
Optimi is a Canadian GMP‑compliant manufacturer of controlled psychedelic substances (MDMA and botanical psilocybin), supplying regulated markets such as Australia and certain Canadian access programs. It reports recurring losses, an accumulated deficit and substantial doubt about its ability to continue as a going concern, and highlights extensive regulatory, financing, competition and product‑liability risks. Optimi is an emerging growth company and a foreign private issuer, using IFRS and benefiting from reduced U.S. reporting and governance requirements.
Optimi Health Corp. (OPTH) entered into a common share purchase agreement with Seven Knots, LLC, establishing an equity line of credit under which Optimi may, at its discretion, sell up to US$100 million of common shares over the term of the facility. For each draw, Seven Knots must buy the specified shares at 97% of the lower of the lowest sale price on the purchase date and the volume-weighted average price during the purchase period, with a maximum of US$2 million per draw and a price floor set at 85% of the prior day’s close or a higher Company-selected floor.
As consideration, Optimi issued Seven Knots a non-interest-bearing US$1.5 million unsecured convertible promissory note and agreed to issue a second US$500,000 note if gross ELOC sales reach US$7 million. These notes mature in 24 months and are convertible at 95% of the 20-day volume-weighted average price, with a minimum conversion price of US$3.00 per share and a 2.99% beneficial ownership cap. Optimi may prepay the notes at 100% of principal in cash, and no shares can be sold under the ELOC until a filed Form F-1 resale registration statement is declared effective by the SEC.
Optimi Health Corp. (OPTH) filed a Form F-1 to register for resale by Seven Knots, LLC up to 21,943,260 common shares, consisting of up to 21,276,593 purchase shares under a common share purchase agreement and up to 666,667 commitment shares issuable upon conversion of Seven Knots Commitment Notes. Optimi is not selling shares in this prospectus and will not receive proceeds from Seven Knots’ resale, though it may receive up to $100 million in gross proceeds from future share sales to Seven Knots under the purchase agreement.
The registered shares equal about 383.2% of the 5,725,867 common shares outstanding, implying very high potential dilution and selling pressure. Optimi is a Canadian GMP-compliant manufacturer of MDMA and psilocybin products for regulated markets such as Australia and Canada’s Special Access Program, operating under a Drug Establishment Licence, Dealer’s Licence and Precursor Licence.
Financially, the company generated C$239,700 in revenue for the nine months ended June 30, 2026 and incurred a loss of C$5,552,091, with an accumulated deficit of C$31,360,001. Risk disclosures highlight substantial doubt about its ability to continue as a going concern, heavy regulatory dependence for psychedelic products and the possibility that large resales could significantly depress the share price and constrain future equity financing.
Optimi Health Corp. established a discretionary equity line of credit with Seven Knots, LLC, allowing Optimi to sell up to US$100 million of common shares over time. Draws are at Optimi’s option, with Seven Knots required to buy at 97% of the lower of the purchase-date low or the volume-weighted average price, capped at US$2 million per draw and subject to a price floor at 85% of the prior close or a higher floor Optimi may set.
Seven Knots cannot exceed 4.99% beneficial ownership from ELOC purchases. As commitment consideration, Optimi issued a US$1.5 million unsecured, non-interest-bearing convertible note and may issue a second US$500,000 note if ELOC proceeds reach US$7 million. These notes mature in 24 months and are convertible at 95% of the 20-day VWAP, with a US$3.00 per-share floor and a separate 2.99% ownership cap on conversion. Optimi can fully prepay the notes in cash or shares at par to stop further share issuance. Joseph Gunnar & Co. LLC will receive a 3% fee on ELOC gross proceeds. Resale of shares under the ELOC and notes will be registered on a Form F-1, and no ELOC sales can occur until that registration is effective.
Optimi Health Corp. reports nine-month revenue to June 30, 2026 of $239,700, down from $490,330 a year earlier, and a wider net loss of $5.6 million (loss per share $1.55 vs. $0.74). Management attributes lower revenue mainly to Australian customers drawing down previously shipped product, resulting in fewer new exports.
The company strengthened its balance sheet through a Nasdaq Capital Market underwritten public offering, issuing 2.4 million shares for gross proceeds of $20.7 million, repaying $1 million of loans and converting $450,000 of convertible debt. Cash and equivalents rose to $13.1 million, supporting positive working capital of $5.9 million.
Optimi continues to position itself as a GMP-certified psychedelics manufacturer, leveraging its Health Canada Drug Establishment Licence and long-term Australian distribution agreement. However, operations remain loss-making, with expenses of $5.7 million driven by amortization, interest, consulting, investor relations linked to the U.S. listing, and wages.
Optimi Health Corp. received a Schedule 13G reporting that Cathay Visions Enterprises Inc. and its sole owner, Dane Nicholas Stevens, beneficially own 474,124 common shares, representing 8.25% of the company’s common share class. The holding consists of 456,347 common shares plus options and warrants exercisable for 17,777 common shares. Both Cathay Visions and Stevens report sole voting and dispositive power over the same 474,124 shares and no shared voting or dispositive power.
Optimi Health Corp., a foreign private issuer, reports that its Chief Executive Officer, Dane Stevens, completed an open market purchase of 3,800 common shares of Optimi Health Corp. at CDN$6.70 per share on August 5, 2026. The transaction was executed indirectly through Cathay Visions Enterprises Ltd., a company controlled by Mr. Stevens. Following this purchase, Mr. Stevens beneficially holds 456,347 common shares of Optimi Health Corp., updating the disclosed insider ownership position. The company provided this information in a SEDI Report Statement submitted to securities regulators.